Drug intelligence / Profile preview

bixolecumab

Development stage: Unknown
Lead developer: Akeso
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Bixolecumab is a humanized monoclonal antibody designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Developed by Kangrong Oriental (Guangdong) Pharmaceutical, it is primarily indicated for the treatment of primary hypercholesterolemia and mixed dyslipidemia. The drug functions by binding to circulating PCSK9, preventing it from interacting with low-density lipoprotein receptors (LDLR) on the surface of hepatocytes. By inhibiting PCSK9-mediated degradation of LDLR, bixolecumab increases the density of these receptors, thereby enhancing the clearance of LDL cholesterol from the bloodstream. It is currently undergoing Phase 3 clinical evaluation in China.

Brand names: Yixin Ning

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on bixolecumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bixolecumab.

Explore the full profile